BioCentury | Nov 21, 2016

LG’s biotech legacy

LG Life Sciences Ltd. was a pioneer, producing the first globally approved drugs developed by a South Korean company. A shift in priorities all but stopped the flow of innovative new drugs to the world...
BioCentury | Mar 21, 2016
Product Development

Korea rising

The Korean biopharma industry is mainly known for biosimilars and me-too products. But a cohort of innovator biotechs in Korea is coming of age, bolstered by an infusion of cash from the government and by...
BC Week In Review | Feb 16, 2015
Clinical News

Acelex polmacoxib regulatory update

South Korea's Ministry of Food and Drug Safety (MFDS) approved an NDA from CrystalGenomics for Acelex polmacoxib to treat osteoarthritis. The product is a dual-acting cyclooxygenase-2 (COX-2) and carbonic anhydrase inhibitor. CrystalGenomics Inc . (KOSDAQ:083790), Seongnam,...
BC Week In Review | Feb 16, 2015
Company News

CrystalGenomics, Daewoong Pharmaceutical deal

CrystalGenomics granted Daewoong exclusive rights to commercialize Acelex polmacoxib to treat osteoarthritis in Korea. CrystalGenomics will receive an upfront payment and is eligible for milestone payments and profit sharing. The dual-acting cyclooxygenase-2 (COX-2) and carbonic...
BC Week In Review | Sep 15, 2014
Clinical News

CrystalGenomics preclinical data

In a premalignant mouse prevention study, polmacoxib was effective in reducing polyp number and size in both the small and large intestines. In a premalignant mouse treatment study, polmacoxib led to significant growth suppression of...
BC Week In Review | Jun 30, 2014
Clinical News

Polmacoxib regulatory update

CrystalGenomics disclosed it submitted an NDA last month to South Korea’s Ministry of Food and Drug Safety (MFDS) for polmacoxib to treat osteoarthritis. The company expects a decision by year end. Polmacoxib is a dual-acting...
BioCentury | Jun 30, 2014

Highlights of weekly biotech stock moves

Regulatory milestones Basilea Pharmaceutica AG (SIX:BSLN) fell CHF9.10 to CHF104.90 last week after it said FDA confirmed additional Phase III data would be required to support U.S. approval of ceftobiprole to treat pneumonia. The company...
BC Extra | Jun 26, 2014
Financial News

CrystalGenomics raises $13 million from Korean fund

CrystalGenomics Inc. (KOSDAQ:083790) raised W13 billion ($13 million) from South Korea's Ministry of Health and Welfare. The investment came from a W100 billion ($100 million) ministry fund to promote globalization of the Korean pharmaceutical industry....
BioCentury | Apr 7, 2014

1Q Stock Wrap-Up: Small but mighty

Despite a correction at the end of March, all biotech market cap segments finished the first quarter in positive territory. Microcaps set the pace with a 10% gain, while large caps added 7% and were...
BC Week In Review | Mar 17, 2014
Clinical News

Polmacoxib: Phase III data

A double-blind, South Korean Phase III trial in 362 patients ages >=20 with OA of the knee or hip showed that once-daily 2 mg oral polmacoxib was non-inferior to once-daily 200 mg celecoxib and superior...
Items per page:
1 - 10 of 25